Could cause temporary or reversible harm; serious harm is unlikely.
Subpotent Drug: Low out of specification assay results performed during long-term stability testing.
| Brand name | NYSTATIN |
| Generic name | NYSTATIN |
| Active ingredient(s) | NYSTATIN |
| Distributed by / for | Padagis US LLC |
| NDC | 45802-059-35 |
| Full product label | Nystatin Cream USP, (100,000 USP Nystatin Units), NET WT 15 g, Rx only, 15 g tube, Manufactured by Padagis, Yeruham, Israel, NDC 45802-059-35 |
| Recalling firm | Padagis US LLC |
| Distribution | USA Nationwide |
| Quantity | 180,936 tubes |
| Recall initiated | 2026-06-23 |
| Report date | 2026-07-22 |
| Recall completed | — |
| Recall number | D-0677-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Minneapolis MN United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗